Effectiveness of Alpha and hydrocortisone %1 ointment to prevent severe skin complications among patients with breast cancer

Comparing the effectiveness of Alpha and hydrocortisone %1 ointment to prevent severe skin complications among patients with breast cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015052114333N34

Enrollment

Registered

2015-07-20

Start date

2014-12-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer. Malignant neoplasm of breast

Interventions

Intervention 1: Patients in the first group used a thin layer of alpha ointment produced by Alpha Tose company twice a day (a centimeter of ointment for 10*10 cm) on radiated area. The ointment is app

Treatment - Drugs

Patients in the first group used a thin layer of alpha ointment produced by Alpha Tose company twice a day (a centimeter of ointment for 10*10 cm) on radiated area. The ointment is applied 2 hours aft

The second group used a thin layer of hydrocortisone %1 ointment produced by Sina company twice a day (a centimeter of ointment for 10*10 cm) on radiated area. The ointment is applied 2 hours after r

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Inclusion criteria: written consent by patients; being treated by final mastectomy; at least three weeks after the last session of chemotherapy; having no burn, cut, infection and skin problems on radiation area. Exclusion criteria: having a history on collagen diseases, cases of diabetes through treatment; using systematic steroids; intolerance of radiation.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Itching. Timepoint: Beginning of study, once a week and end of the study(6 to 7 weeks after beginning). Method of measurement: Asking the patients.;Irritation. Timepoint: Beginning of study, once a week and end of the study(6 to 7 weeks after beginning). Method of measurement: Asking the patients.;Pain levels. Timepoint: Beginning of study, once a week and end of the study(6 to 7 weeks after beginning). Method of measurement: Asking from the patients.;Severe skin complications. Timepoint: Beginning of study, once a week and end of the study(6 to 7 weeks after beginning). Method of measurement: Based on observations and physician examination, RTOG according to the criterion.	—

Measure

Time frame

Itching. Timepoint: Beginning of study, once a week and end of the study(6 to 7 weeks after beginning). Method of measurement: Asking the patients.;Irritation. Timepoint: Beginning of study, once a week and end of the study(6 to 7 weeks after beginning). Method of measurement: Asking the patients.;Pain levels. Timepoint: Beginning of study, once a week and end of the study(6 to 7 weeks after beginning). Method of measurement: Asking from the patients.;Severe skin complications. Timepoint: Beginning of study, once a week and end of the study(6 to 7 weeks after beginning). Method of measurement: Based on observations and physician examination, RTOG according to the criterion.

—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026